Member-only story

Pharmacovigilance in the European Union: A Comprehensive Guide

Isaac Asimov

·5.9k Followers· Follow

Published in Pharmacovigilance In The European Union: Practical Implementation Across Member States

4 min read · 3 weeks before

868 View Claps

70 Respond

Save

Listen

Pharmacovigilance is the science and practice of monitoring the safety of medicines after they have been marketed. In the European Union, pharmacovigilance is regulated by a number of laws and regulations, which are designed to ensure that medicines are safe and effective for use.

Pharmacovigilance in the European Union: Practical Implementation across Member States

by Colin Seymour-Ure

4 out of 5

Language	:	English
File size	:	9108 KB
Text-to-Speech	:	Enabled
Screen Reader	:	Supported
Enhanced typesetting	:	Enabled
Word Wise	:	Enabled
Print length	:	135 pages

The legal framework for pharmacovigilance in the European Union is based on the following principles:

Medicines must be monitored for safety throughout their lifecycle.
Marketing authorisations are granted on the basis of a risk-benefit assessment.
Manufacturers are responsible for the safety of their products.
Patients have a right to be informed about the risks and benefits of medicines.

The European Medicines Agency (EMA) is responsible for coordinating pharmacovigilance activities in the European Union. The EMA works with national competent authorities and other stakeholders to ensure that medicines are safe and effective for use.

The key principles of pharmacovigilance include:

Early detection of adverse events: Adverse events are any untoward medical occurrences that may be associated with the use of a medicine. Early detection of adverse events is essential for identifying potential safety concerns.
Assessment of the risks and benefits of medicines: The risks and benefits of medicines are assessed on an ongoing basis, taking into account new information from clinical trials, post-marketing surveillance, and other sources.
Communication of safety information to healthcare professionals and patients: Healthcare professionals and patients need to be informed about the risks and benefits of medicines in Free Download to make informed decisions about their use.

The practices of pharmacovigilance include:

Collection of data on adverse events: Data on adverse events are collected from a variety of sources, including spontaneous reports from healthcare professionals and patients, clinical trials, and post-marketing surveillance studies.
Assessment of the data: Data on adverse events are assessed to identify potential safety concerns. This assessment may involve statistical analysis, literature reviews, and expert opinion.
Communication of safety information: Safety information is communicated to healthcare professionals and patients through a variety of channels, including product labels, package inserts, and online resources.

Pharmacovigilance is an essential part of ensuring the safety of medicines in the European Union. The legal framework, the roles and responsibilities of different stakeholders, and the key principles and practices of pharmacovigilance all contribute to ensuring that medicines are safe and effective for use.